بررسی تاثیر ان استیل سیستئین بر روی علایم منفی اسکیزوفرنی

فرخ نیا, مهدی and آذرکلاه, آنیتا and آدینه فر, فرود and خدایی اردکانی, محمدرضا and حسینی, سید محمدرضا and یکته تاز, حبیبه and تبریزی, مینا and رضائی, فرزین and صالحی, بهمن and صادقی, سید محمد حسین and مقدم‌, مرضیه and غریبی, فردین and میرشفیعی, امید and آخوندزاده, شاهین (1392) بررسی تاثیر ان استیل سیستئین بر روی علایم منفی اسکیزوفرنی. Clinical Neuropharmacology ــ 36 (6). pp. 185-195. شاپا 0362-5664


Official URL: http://journals.lww.com/clinicalneuropharm/pages/d...


N-acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study

English Abstract

Objectives: Despite the burden of negative symptoms on quality of life in schizophrenic patients, no completely effective treatment has been developed to address such symptoms yet. Abnormalities in oxidative stress pathways have been recently demonstrated to be involved in the pathophysiology of schizophrenia, and a growing interest in antioxidant agents is emerging for targeting negative symptoms of schizophrenia. N-acetylcysteine (NAC) is a potent antioxidant with neuroprotective properties. This study aimed to evaluate the possible effects of NAC as an adjunct to risperidone in treating negative symptoms of schizophrenia. Materials and Methods: In this randomized double-blind, placebocontrolled, parallel-group study, 42 patients with chronic schizophrenia with a score of 20 or greater on the negative subscale of positive and negative syndrome scale (PANSS) were enrolled in the active phase of their illness. The participants were equally randomized to receive NAC (up to 2 g/d) or placebo, in addition to risperidone (up to 6 mg/d) for 8 weeks. The participants were rated using PANSS every 2 weeks, and a decrease in PANSS negative subscale score was considered as our primary outcome. Results: By the study end point, NAC-treated patients showed significantly greater improvement in the PANSS total (P = 0.006) and negative subscale (P < 0.001) scores than that in the placebo group, but this difference was not significant for positive and general psychopathology subscales. There was no significant difference between the 2 groups in the frequency of adverse effects. Conclusions: N-acetylcysteine add-on therapy showed to be a safe and effective augmentative strategy for alleviating negative symptoms of schizophrenia.

Item Type:Article
زبان سند : انگلیسی
نویسنده اول :مهدی فرخ نیا
نویسنده مسئول :شاهین آخوندزاده
Additional Information:Impact Factor (2013) 1.836 Indexed in: ISI, Scopus, Chemical Abstracts
کلیدواژه ها (انگلیسی):antioxidant, glutamate, N-acetylcysteine, negative symptoms, schizophrenia
Subjects:WM Psychiatry
Divisions:Faculty of Medicine > Department of Dermatology , Psychiatry , Neurology
ID Code:8229
Deposited By: دکتر بیتا شهباززادگان
Deposited On:07 Oct 1395 08:07
Last Modified:20 Jan 1397 13:27

Repository Staff Only: item control page

Document Downloads

More statistics for this item...